Literature DB >> 22740343

Distribution of prolyl oligopeptidase in human peripheral tissues and in ovarian and colorectal tumors.

Timo T Myöhänen1, Elisa Pyykkö, Pekka T Männistö, Olli Carpen.   

Abstract

Prolyl oligopeptidase (PREP) is a serine protease that hydrolyzes peptides shorter than 30-mer, and it has been connected with multiple physiological and pathological conditions. PREP has been mostly studied in the brain, but significant PREP activities have been measured in peripheral tissues. Moreover, increased PREP activities have been found in tumors. In this study, the authors studied the immunohistochemical distribution of PREP protein in human peripheral tissues and in ovarian and colorectal tumors. PREP was found to be widely distributed in human peripheral tissues and specifically in certain cells. The most intense PREP expression was seen in the testis, ovaries, liver, and some parts of the skin. At the cellular level, high PREP levels were seen as a rule in secreting epithelial cells and cells involved in reproduction. Increased PREP expression was seen in most of the tumors studied. PREP expression was higher in malignant than benign tumors, and in ovarian epithelial cancers, there was a trend for increased PREP staining with increased malignancy grade. Results suggest that PREP may be associated with secretory processes as well as in reproduction. A more abundant expression of PREP in malignant than benign tumors suggests that PREP may be associated with expansion and metastasis of tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22740343      PMCID: PMC3524555          DOI: 10.1369/0022155412453051

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  47 in total

1.  Effect of aging on rat tissue peptidase activities.

Authors:  Naiara Agirregoitia; Javier Gil; Fátima Ruiz; Jon Irazusta; Luis Casis
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2003-09       Impact factor: 6.053

2.  Large-scale analysis of the human and mouse transcriptomes.

Authors:  Andrew I Su; Michael P Cooke; Keith A Ching; Yaron Hakak; John R Walker; Tim Wiltshire; Anthony P Orth; Raquel G Vega; Lisa M Sapinoso; Aziz Moqrich; Ardem Patapoutian; Garret M Hampton; Peter G Schultz; John B Hogenesch
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-19       Impact factor: 11.205

3.  Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.

Authors:  T T Myöhänen; J Tenorio-Laranga; B Jokinen; R Vázquez-Sánchez; M J Moreno-Baylach; J A García-Horsman; P T Männistö
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

4.  Lithium therapy and signal transduction.

Authors:  R S Williams; A J Harwood
Journal:  Trends Pharmacol Sci       Date:  2000-02       Impact factor: 14.819

5.  A common mechanism of action for three mood-stabilizing drugs.

Authors:  Robin S B Williams; Lili Cheng; Anne W Mudge; Adrian J Harwood
Journal:  Nature       Date:  2002-05-16       Impact factor: 49.962

6.  Expression and localization of prolyl oligopeptidase in mouse testis and its possible involvement in sperm motility.

Authors:  Atsushi Kimura; Hitoshi Matsui; Takayuki Takahashi
Journal:  Zoolog Sci       Date:  2002-01       Impact factor: 0.931

7.  Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819.

Authors:  Jarkko I Venäläinen; Risto O Juvonen; Markus M Forsberg; Arturo Garcia-Horsman; Antti Poso; Erik A A Wallen; Jukka Gynther; Pekka T Männistö
Journal:  Biochem Pharmacol       Date:  2002-08-01       Impact factor: 5.858

8.  Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition.

Authors:  Ingo Schulz; Bernd Gerhartz; Antje Neubauer; Andreas Holloschi; Ulrich Heiser; Mathias Hafner; Hans-Ulrich Demuth
Journal:  Eur J Biochem       Date:  2002-12

9.  Ontogeny of soluble and particulate prolyl endopeptidase activity in several areas of the rat brain and in the pituitary gland.

Authors:  Naiara Agirregoitia; Amaia Irazusta; Fátima Ruiz; Jon Irazusta; Javier Gil
Journal:  Dev Neurosci       Date:  2003 Sep-Oct       Impact factor: 2.984

10.  Localization of the mRNA encoding prolyl endopeptidase in the rat brain and pituitary.

Authors:  Gaelle Bellemère; Hubert Vaudry; Lourdes Mounien; Isabelle Boutelet; Sylvie Jégou
Journal:  J Comp Neurol       Date:  2004-03-29       Impact factor: 3.215

View more
  18 in total

1.  Tetrazole as a Replacement of the Electrophilic Group in Characteristic Prolyl Oligopeptidase Inhibitors.

Authors:  Tommi P Kilpeläinen; Jonna K Tyni; Maija K Lahtela-Kakkonen; Tony S Eteläinen; Timo T Myöhänen; Erik A A Wallén
Journal:  ACS Med Chem Lett       Date:  2019-11-11       Impact factor: 4.345

Review 2.  The expression of proline-specific enzymes in the human lung.

Authors:  Gwendolyn Vliegen; Tom K Raju; Dirk Adriaensen; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Ann Transl Med       Date:  2017-03

3.  Prolyl oligopeptidase attenuates hepatic stellate cell activation through induction of Smad7 and PPAR-γ.

Authors:  Da Zhou; Jing Wang; Ling-Nan He; Bing-Hang Li; Yong-Nian Ding; Yuan-Wen Chen; Jian-Gao Fan
Journal:  Exp Ther Med       Date:  2017-01-05       Impact factor: 2.447

4.  Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase.

Authors:  Sarah E Poplawski; Jack H Lai; Youhua Li; Zhiping Jin; Yuxin Liu; Wengen Wu; Yong Wu; Yuhong Zhou; James L Sudmeier; David G Sanford; William W Bachovchin
Journal:  J Med Chem       Date:  2013-04-29       Impact factor: 7.446

5.  Prolyl endopeptidase inhibitor Y-29794 blocks the IRS1-AKT-mTORC1 pathway and inhibits survival and in vivo tumor growth of triple-negative breast cancer.

Authors:  Ricardo E Perez; Sarah Calhoun; Daeun Shim; Victor V Levenson; Lei Duan; Carl G Maki
Journal:  Cancer Biol Ther       Date:  2020-10-12       Impact factor: 4.742

6.  Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent.

Authors:  Peter Serfozo; Jan Wysocki; Gvantca Gulua; Arndt Schulze; Minghao Ye; Pan Liu; Jing Jin; Michael Bader; Timo Myöhänen; J Arturo García-Horsman; Daniel Batlle
Journal:  Hypertension       Date:  2019-12-02       Impact factor: 10.190

7.  Altered Activity and Expression of Cytosolic Peptidases in Colorectal Cancer.

Authors:  Itxaro Perez; Lorena Blanco; Begoña Sanz; Peio Errarte; Usue Ariz; Maider Beitia; Ainhoa Fernández; Alberto Loizate; M Luz Candenas; Francisco M Pinto; Javier Gil; José I López; Gorka Larrinaga
Journal:  Int J Med Sci       Date:  2015-06-02       Impact factor: 3.738

8.  Suppression of tumor growth in mice by rationally designed pseudopeptide inhibitors of fibroblast activation protein and prolyl oligopeptidase.

Authors:  Kenneth W Jackson; Victoria J Christiansen; Vivek R Yadav; Robert Silasi-Mansat; Florea Lupu; Vibhudutta Awasthi; Roy R Zhang; Patrick A McKee
Journal:  Neoplasia       Date:  2015-01       Impact factor: 5.715

9.  Catechol-O-methyltransferase (COMT) protein expression and activity after dopaminergic and noradrenergic lesions of the rat brain.

Authors:  Nadia Schendzielorz; Juha-Pekka Oinas; Timo T Myöhänen; Ilkka Reenilä; Atso Raasmaja; Pekka T Männistö
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

10.  Prolyl endopeptidase activity is correlated with colorectal cancer prognosis.

Authors:  Gorka Larrinaga; Itxaro Perez; Lorena Blanco; Begoña Sanz; Peio Errarte; Maider Beitia; María C Etxezarraga; Alberto Loizate; Javier Gil; Jon Irazusta; José I López
Journal:  Int J Med Sci       Date:  2014-01-10       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.